Sugi Predict

Sugi Predict / Compounds / SCHEMBL16296223

SCHEMBL16296223

SCHEMBL16296223

Nc1nc2cnc(Br)cn2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.37
▸ PAK4 O96013 1/20 0.37
▸ CSF1R P07333 1/20 0.37
▸ RET P07949 1/20 0.37
▸ GRK5 P34947 1/20 0.37
▸ MAPK8 P45983 1/20 0.37
▸ CSNK1A1 P48729 1/20 0.37
▸ ACVR1 Q04771 1/20 0.37
▸ PTK2 Q05397 1/20 0.37
▸ TYRO3 Q06418 1/20 0.37
▸ MAP4K2 Q12851 1/20 0.37
▸ DYRK1A Q13627 1/20 0.37
▸ IKBKE Q14164 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ DYRK1B Q9Y463 1/20 0.37
▸ PIK3CD O00329 6/20 0.35
▸ PIK3CG P48736 6/20 0.35
▸ PIK3CA P42336 3/20 0.35
▸ PIK3CB P42338 2/20 0.35
▸ NUDT1 P36639 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31600050 0.77 AHR (0.33) DYRK1A
SCHEMBL30547140 0.77 MAP4K4 (0.37) MAP4K4PAK4CSF1RRETGRK5
SCHEMBL43051 0.71 AHR (0.58) PIK3CDPIK3CGPIK3CAPIK3CB
SCHEMBL16296349 0.70 CHEK1 (0.44) MAP4K4PAK4CSF1RRETGRK5
SCHEMBL30385817 0.70 NUDT1 (0.36) MAP4K4PAK4CSF1RRETGRK5
SCHEMBL30728843 0.67 CHEK1 (0.50) MAP4K4PAK4CSF1RRETGRK5
SCHEMBL16439310 0.67 PDE10A (0.41) PIK3CDPIK3CGPIK3CAPIK3CBNUDT1
SCHEMBL16439356 0.67 PIK3CG (0.34) PIK3CDPIK3CGPIK3CAPIK3CBNUDT1
SCHEMBL31489439 0.67 KDM4E (0.41) PIK3CDPIK3CGPIK3CAPIK3CBNUDT1
SCHEMBL27037698 0.67 PIK3CG (0.40) PIK3CDPIK3CGPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4736856-A2 BICYCLIC AMINES AS CDK2 INHIBITORS Incyte Corporation (US) 2026-05-06 — — EP disclosed
EP-4041731-B1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORP (US) 2026-02-18 — — EP disclosed
US-20260022119-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2026-01-22 — — US disclosed
US-12466828-B2 Bicyclic amines as CDK2 inhibitors INCYTE CORPORATION (US) 2025-11-11 — — US disclosed
CN-119930611-A Bicyclic amines as CDK2 inhibitors 因赛特公司 2025-05-06 — — CN disclosed
CN-119930610-A Bicyclic amines as CDK2 inhibitors 因赛特公司 2025-05-06 — — CN disclosed
CN-115298177-B Bicyclic amines as CDK2 inhibitors 因赛特公司 2025-01-17 — — CN disclosed
US-20240174664-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2024-05-30 — — US disclosed
US-11851426-B2 Bicyclic amines as CDK2 inhibitors INCYTE CORPORATION (US) 2023-12-26 — — US disclosed
CN-116262739-A Nitrogen-containing aryl derivative regulator, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-06-16 — — CN disclosed
US-20210107901-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2021-04-15 — — US disclosed
US-20210107901-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2021-04-15 — — US disclosed
WO-2021072232-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION (US) 2021-04-15 — — WO disclosed
WO-2021072232-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION (US) 2021-04-15 — — WO disclosed
US-20160207928-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-21 — — US disclosed
US-20160207928-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-21 — — US disclosed
US-20160207928-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-21 — — US disclosed
EP-3008061-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER Bayer Pharma Aktiengesellschaft (DE) 2016-04-20 — — EP disclosed
WO-2014198594-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-12-18 — — WO disclosed
WO-2014198594-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022119-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CCNA1, CDK1, CCNE1 MAP4K4 1395/4885PAK4 3984/4885CSF1R 1782/4885
US-11851426-B2 Bicyclic amines as CDK2 inhibitors CDK2, CDK1, CCNI MAP4K4 199/4885PAK4 485/4885CSF1R 3720/4885
US-20240174664-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CDK2, CDK1, CCNI MAP4K4 199/4885PAK4 485/4885CSF1R 3720/4885
US-20210107901-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CDK2, CDK1, CCNI MAP4K4 199/4885PAK4 485/4885CSF1R 3720/4885
US-12466828-B2 Bicyclic amines as CDK2 inhibitors CDK2, CDK1, CCNI MAP4K4 199/4885PAK4 485/4885CSF1R 3720/4885
US-20160207928-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER BUB1B, PLK1, BRCA1 MAP4K4 253/4885PAK4 822/4885CSF1R 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.